drugset / Trial / NCT00354094

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

NCT00354094

Phase 2 Terminated 600 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of \[S,S\]-Reboxetine in patients with pain after shingles.

Timeline

Start
2006-11
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject [S,S]-Reboxetine Unknown

Indications

No indication recorded.